Pfizer Cools To Tax Inversion After Nixed Allergan Deal
By Erin Coe · May 4, 2016, 9:25 PM EDT
Pfizer Inc. said Tuesday it isn't inclined to seek another inversion transaction after it scrapped a proposed $160 billion merger with Irish drugmaker Allergan in April in light of the U.S....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login